A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease.

<h4>Background</h4>Psychopharmacotherapy currently constitutes the first-line treatment for depression and anxiety in Parkinson's disease (PD) however the efficacy of antidepressant treatments in PD is unclear. Several alternative treatments have been suggested as potentially more v...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lakkhina Troeung, Sarah J Egan, Natalie Gasson
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5424ccb1e5514e638ff165634a4ca232
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5424ccb1e5514e638ff165634a4ca232
record_format	dspace
spelling	oai:doaj.org-article:5424ccb1e5514e638ff165634a4ca2322021-11-18T08:46:45ZA meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease.1932-620310.1371/journal.pone.0079510https://doaj.org/article/5424ccb1e5514e638ff165634a4ca2322013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24236141/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Psychopharmacotherapy currently constitutes the first-line treatment for depression and anxiety in Parkinson's disease (PD) however the efficacy of antidepressant treatments in PD is unclear. Several alternative treatments have been suggested as potentially more viable alternatives including dopamine agonists, repetitive transcranial magnetic stimulation, and cognitive behavioural therapy (CBT).<h4>Method</h4>A meta-analysis of randomised placebo-controlled trials for depression and/or anxiety in PD was conducted to systematically examine the efficacy of current treatments for depression and anxiety in PD.<h4>Results</h4>Nine trials were included. There was only sufficient data to calculate a pooled effect for antidepressant therapies. The pooled effect of antidepressants for depression in PD was moderate but non-significant (d = .71, 95% CI = -1.33 to 3.08). The secondary effect of antidepressants on anxiety in PD was large but also non-significant (d = 1.13, 95% CI = -.67 to 2.94). Two single-trials of non-pharmacological treatments for depression in PD resulted in significant large effects; Omega-3 supplementation (d = .92, 95% CI = .15 to 1.69) and CBT (d = 1.57, 95% CI = 1.06 to 2.07), and warrant further exploration.<h4>Conclusions</h4>There remains a lack of controlled trials for both pharmacological and non-pharmacological treatments for depression and anxiety in PD which limits the conclusions which can be drawn. While the pooled effects of antidepressant therapies in PD were non-significant, the moderate to large magnitude of each pooled effect is promising. Non-pharmacological approaches show potential for depression in PD however more research is required.Lakkhina TroeungSarah J EganNatalie GassonPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 11, p e79510 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Lakkhina Troeung Sarah J Egan Natalie Gasson A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease.
description	<h4>Background</h4>Psychopharmacotherapy currently constitutes the first-line treatment for depression and anxiety in Parkinson's disease (PD) however the efficacy of antidepressant treatments in PD is unclear. Several alternative treatments have been suggested as potentially more viable alternatives including dopamine agonists, repetitive transcranial magnetic stimulation, and cognitive behavioural therapy (CBT).<h4>Method</h4>A meta-analysis of randomised placebo-controlled trials for depression and/or anxiety in PD was conducted to systematically examine the efficacy of current treatments for depression and anxiety in PD.<h4>Results</h4>Nine trials were included. There was only sufficient data to calculate a pooled effect for antidepressant therapies. The pooled effect of antidepressants for depression in PD was moderate but non-significant (d = .71, 95% CI = -1.33 to 3.08). The secondary effect of antidepressants on anxiety in PD was large but also non-significant (d = 1.13, 95% CI = -.67 to 2.94). Two single-trials of non-pharmacological treatments for depression in PD resulted in significant large effects; Omega-3 supplementation (d = .92, 95% CI = .15 to 1.69) and CBT (d = 1.57, 95% CI = 1.06 to 2.07), and warrant further exploration.<h4>Conclusions</h4>There remains a lack of controlled trials for both pharmacological and non-pharmacological treatments for depression and anxiety in PD which limits the conclusions which can be drawn. While the pooled effects of antidepressant therapies in PD were non-significant, the moderate to large magnitude of each pooled effect is promising. Non-pharmacological approaches show potential for depression in PD however more research is required.
format	article
author	Lakkhina Troeung Sarah J Egan Natalie Gasson
author_facet	Lakkhina Troeung Sarah J Egan Natalie Gasson
author_sort	Lakkhina Troeung
title	A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease.
title_short	A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease.
title_full	A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease.
title_fullStr	A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease.
title_full_unstemmed	A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease.
title_sort	meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in parkinson's disease.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/5424ccb1e5514e638ff165634a4ca232
work_keys_str_mv	AT lakkhinatroeung ametaanalysisofrandomisedplacebocontrolledtreatmenttrialsfordepressionandanxietyinparkinsonsdisease AT sarahjegan ametaanalysisofrandomisedplacebocontrolledtreatmenttrialsfordepressionandanxietyinparkinsonsdisease AT nataliegasson ametaanalysisofrandomisedplacebocontrolledtreatmenttrialsfordepressionandanxietyinparkinsonsdisease AT lakkhinatroeung metaanalysisofrandomisedplacebocontrolledtreatmenttrialsfordepressionandanxietyinparkinsonsdisease AT sarahjegan metaanalysisofrandomisedplacebocontrolledtreatmenttrialsfordepressionandanxietyinparkinsonsdisease AT nataliegasson metaanalysisofrandomisedplacebocontrolledtreatmenttrialsfordepressionandanxietyinparkinsonsdisease
_version_	1718421321907437568

A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease.

Ejemplares similares